Ragweed sublingual tablet immunotherapy

Part i - Evidence-based clinical efficacy and safety

Research output: Contribution to journalReview article

Abstract

Sublingual tablet immunotherapy provides an attractive alternative approach to allergen immunotherapy, as the allergen is administered as a rapidly dissolving sublingual tablet. Part I of this two-part series on the ragweed sublingual tablet describes the dose-ranging clinical work, the safety studies and the clinical outcomes from the pivotal trials which provide clear evidence for statistically significant and clinically meaningful benefit in the treatment of patients suffering from ragweed-induced seasonal allergic rhinitis-conjunctivitis with or without milder asthma. The robust results observed in the clinical trials performed with the ragweed sublingual tablet are defined by the quality of their study design, their use of a standardized allergen extract, their consistent reproducibility in demonstrating therapeutic efficacy and their properly quantified and graded safety data.

Original languageEnglish (US)
Pages (from-to)605-616
Number of pages12
JournalImmunotherapy
Volume10
Issue number7
DOIs
StatePublished - Jun 1 2018

Fingerprint

Sublingual Immunotherapy
Ambrosia
Tablets
Safety
Allergens
Immunologic Desensitization
Allergic Conjunctivitis
Seasonal Allergic Rhinitis
Asthma
Outcome Assessment (Health Care)
Clinical Trials
Therapeutics

Keywords

  • allergen immunotherapy
  • allergic rhinitis/conjunctivitis
  • ragweed
  • ragweed pollen
  • ragweed subcutaneous immunotherapy
  • ragweed sublingual immunotherapy
  • ragweed sublingual tablet

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Ragweed sublingual tablet immunotherapy : Part i - Evidence-based clinical efficacy and safety. / Creticos, Peter Socrates; Pfaar, Oliver.

In: Immunotherapy, Vol. 10, No. 7, 01.06.2018, p. 605-616.

Research output: Contribution to journalReview article

@article{a85ec92dcd684df997d02cf258b6eaa4,
title = "Ragweed sublingual tablet immunotherapy: Part i - Evidence-based clinical efficacy and safety",
abstract = "Sublingual tablet immunotherapy provides an attractive alternative approach to allergen immunotherapy, as the allergen is administered as a rapidly dissolving sublingual tablet. Part I of this two-part series on the ragweed sublingual tablet describes the dose-ranging clinical work, the safety studies and the clinical outcomes from the pivotal trials which provide clear evidence for statistically significant and clinically meaningful benefit in the treatment of patients suffering from ragweed-induced seasonal allergic rhinitis-conjunctivitis with or without milder asthma. The robust results observed in the clinical trials performed with the ragweed sublingual tablet are defined by the quality of their study design, their use of a standardized allergen extract, their consistent reproducibility in demonstrating therapeutic efficacy and their properly quantified and graded safety data.",
keywords = "allergen immunotherapy, allergic rhinitis/conjunctivitis, ragweed, ragweed pollen, ragweed subcutaneous immunotherapy, ragweed sublingual immunotherapy, ragweed sublingual tablet",
author = "Creticos, {Peter Socrates} and Oliver Pfaar",
year = "2018",
month = "6",
day = "1",
doi = "10.2217/imt-2017-0186",
language = "English (US)",
volume = "10",
pages = "605--616",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "7",

}

TY - JOUR

T1 - Ragweed sublingual tablet immunotherapy

T2 - Part i - Evidence-based clinical efficacy and safety

AU - Creticos, Peter Socrates

AU - Pfaar, Oliver

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Sublingual tablet immunotherapy provides an attractive alternative approach to allergen immunotherapy, as the allergen is administered as a rapidly dissolving sublingual tablet. Part I of this two-part series on the ragweed sublingual tablet describes the dose-ranging clinical work, the safety studies and the clinical outcomes from the pivotal trials which provide clear evidence for statistically significant and clinically meaningful benefit in the treatment of patients suffering from ragweed-induced seasonal allergic rhinitis-conjunctivitis with or without milder asthma. The robust results observed in the clinical trials performed with the ragweed sublingual tablet are defined by the quality of their study design, their use of a standardized allergen extract, their consistent reproducibility in demonstrating therapeutic efficacy and their properly quantified and graded safety data.

AB - Sublingual tablet immunotherapy provides an attractive alternative approach to allergen immunotherapy, as the allergen is administered as a rapidly dissolving sublingual tablet. Part I of this two-part series on the ragweed sublingual tablet describes the dose-ranging clinical work, the safety studies and the clinical outcomes from the pivotal trials which provide clear evidence for statistically significant and clinically meaningful benefit in the treatment of patients suffering from ragweed-induced seasonal allergic rhinitis-conjunctivitis with or without milder asthma. The robust results observed in the clinical trials performed with the ragweed sublingual tablet are defined by the quality of their study design, their use of a standardized allergen extract, their consistent reproducibility in demonstrating therapeutic efficacy and their properly quantified and graded safety data.

KW - allergen immunotherapy

KW - allergic rhinitis/conjunctivitis

KW - ragweed

KW - ragweed pollen

KW - ragweed subcutaneous immunotherapy

KW - ragweed sublingual immunotherapy

KW - ragweed sublingual tablet

UR - http://www.scopus.com/inward/record.url?scp=85047856811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047856811&partnerID=8YFLogxK

U2 - 10.2217/imt-2017-0186

DO - 10.2217/imt-2017-0186

M3 - Review article

VL - 10

SP - 605

EP - 616

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 7

ER -